title: [Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist].
abstract: Losartan is the first orally active angiotensin II receptor type 1 antagonist for a new class of cardiovascular therapeutic agent. Losartan is converted to an active metabolite (E3174) after oral administration in humans and rats. Both losartan and E3174 contribute to the net angiotensin II receptor blockade and produce anti-hypertensive effect. Losartan not only blocks the vasoconstrictive effect of angiotensin II but also inhibits its mitogenic effect; thus losartan is expected to protect against end-organ-damage-related hypertension and chronic heart failure. Unlike angiotensin-coverting-enzyme inhibitor, losartan does not elicit adverse effects of cough and angioneurotic edema by its blockade of angiotensin II receptor. It is also expected to reduce proteinuria in nephropathy. In addition to its blockade of angiotensin II receptor, losartan blocks thromboxane A2 receptor and facilitates excretion of uric acid, although therapeutic importance of these effects are under investigation. In summary, losartan, an angiotensin II type 1 receptor antagonist is a new class of antihypertensive agent and its therapeutic potentials are not merely reduction of blood pressure but total protection from end-organ damage resulting from activation of both the systemic and local renin-angiotensin system.
authors.affiliation: Banyu Pharmaceutical Co., Tsukuba Research Institutes, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ohta
authors.forename: T
authors.initials: T
authors.lastname: Satomi
authors.forename: J
authors.initials: J
authors.lastname: Suzuki
authors.forename: F
authors.initials: F
authors.lastname: Ikemoto
authors.forename: M
authors.initials: M
authors.lastname: Nishikibe
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D019808:Losartan / Q000494:pharmacology* / Q000627:therapeutic use; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D012084:Renin-Angiotensin System / Q000502:physiology; D014527:Uric Acid / Q000378:metabolism
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D017482:Receptors, Thromboxane; D014527:Uric Acid; D019808:Losartan